Study: New drug prevents cytomegalovirus in stem cell transplant patients

09/25/2013 | Medscape (free registration)

A new oral antiviral drug that contains cidofovir proved effective in preventing cytomegalovirus infection in patients who had allogeneic hematopoietic cell transplants. A Phase II study published in the New England Journal of Medicine found that 10% of patients treated with CMX001 reported CMV incidence, compared with 37% in a placebo group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX